ClinicalTrials.gg
RecruitingNCT07590934PROSPECTORUpdated Oct 14, 2026

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

A Phase 1/2 interventional study of AZD2265 (FPI-2265) and Palacaparib (AZD9574) in Metastatic Prostate Cancer, sponsored by AstraZeneca. Recruiting at 38 sites in 7 countries. Open to male participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 14, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.

Planned enrollment
23rd of 60
152 · median 110
Started
2026
with 6 others
Phase 1/2
11 of 91
6 open now
Primary completion
2029-09
later than 23 of 28 live
Registered
89th of 91
by date

Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 23rd largest by planned enrollment of the 60 interventional ones that give a count, is one of 7 that started in 2026, is one of 11 in phase 1/2, reaches primary completion later than 23 of the 28 other live ones, and was the 89th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 99 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Prostatic Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.

Read the detailed description

This is a multicentre, open-label and platform study to evaluate multiple anti-cancer agents in participants with metastatic prostate cancer. This platform study will comprise a series of substudies. Each substudy will follow a 2-part structure (unless otherwise stated in the individual substudy):

  • Part A: A dose escalation (DE) phase to identify dose limiting toxicities (DLTs), characterise safety, PK, pharmacodynamics, preliminary efficacy, and determine biologically and clinically suitable dose levels to proceed into the dose optimisation/expansion.
  • Part B: A dose optimisation/expansion phase to inform recommended Phase 3 dose (RP3D), explore efficacy with Prostate-specific antigen (PSA) decrease ≥ 50% (PSA50) rate as primary endpoints, alongside continued safety monitoring.

Sub-study 1 focuses on a specific combination regimen and it will assess the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumour activity of AZD2265 (FPI-2265) actinium (225Ac) zadavotide guraxetan [hereafter referred to as AZD2265 (FPI-2265)] in combination with palacaparib (AZD9574) compared with AZD2265 (FPI-2265) monotherapy and with standard-of-care (SoC) docetaxel chemotherapy in participants with metastatic castration resistant prostate cancer (mCRPC).

03

Conditions studied

  • Metastatic Prostate Cancer

Browse trials for

Keywords

  • Metastatic castration resistant prostate cancer
  • Prostate-specific membrane antigen-targeted radioligand therapy
  • Alpha particle therapy
  • Poly ADP-ribose polymerase 1 (PARP1) inhibitor therapy
  • Combination therapy
  • Docetaxel therapy
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Participants with a diagnosis of confirmed adenocarcinoma of the prostate (no small cell, neuroendocrine, sarcomatoid, spindle or signet cell).
  2. Minimum of 3 months or more.
  3. (ECOG) performance status of O or 1 at screening, with no deterioration.
  4. PCWG3 (Prostate Cancer Working Group 3) modified Version 1.1 evaluable disease.
  5. Must have received at least one novel androgen receptor pathway inhibitor (ARPI), such as enzalutamide or darolutamide or apalutamide or abiraterone acetate.
  6. Must have one or more unresectable lesions.
  7. Must have had prior orchiectomy and/or ongoing androgen deprivation therapy, and a castrate level of serum testosterone (\<50ng/dL or \<l.7nmol/L).
  8. Progressive metastatic castration-resistant prostate cancer (mCRPC) following the most recent treatment at time of study entry.
  9. Adequate organ and marrow function.
  10. Non sterilised participants who are sexually active with a partner of must use a condom (plus spermicide, if available), must refrain from fathering a child, freezing or donating sperm, and it is recommended for the partner to also use a highly effective method.

Inclusion Criteria for Sub study 1:

  1. Must have received a single line of ARPI, such as enzalutamide, darolutamide, apalutamide or abiraterone acetate. Participants who were exposed to more than one ARPI due to toxicity or intolerance (not due to disease progression) are eligible.
  2. PSMA positive mCRPC by computed tomography positron emission tomography, obtained with PSMA ligand defined as at least 1 PSMA positive metastatic lesion with tracer uptake greater than liver, and no PSMA negative lesions. All measurable or intraprostatic lesions must be PSMA positive.
  3. Capable of self-administering oral formulations.

Exclusion Criteria:

  1. Any evidence of non adenocarcinomatous forms of prostate cancer (including small cell, spindle cell, signet cell, neuroendocrine, sarcomatous).
  2. Known, unresolved urinary tract obstruction.
  3. Participants with a history of central nervous system metastases.
  4. Symptomatic malignant spinal cord compression or findings indicative of impending cord compression.
  5. Participants with a history of .
  6. Previous or concurrent cancer distinct from the cancer under investigation in primary site or histology .
  7. Concurrent serious medical conditions.
  8. Previous history of interstitial lung disease or non-infectious pneumonitis.
  9. Participants with a history or clinical/laboratory features suggestive of myelodysplastic syndrome or acute myeloid leukaemia.
  10. Persistent toxicities caused by previous therapy.
  11. Participants unable to swallow orally administered medications or with gastrointestinal disorders likely to interfere with absorption.
  12. Active infection, including tuberculosis, virus, and virus infection.
  13. Known to study intervention or any of their .

Exclusion Criteria for Sub study 1:

  1. History of uncontrolled seizures or requirement for >2 antiepileptic drugs.
  2. History of severe brain injury or stroke.
  3. Skeletal metastases demonstrating a superscan appearance on bone scan.
  4. Participants have received prior therapy with palacaparib (AZD9574) or more than 1 prior line of any other Poly-ADP-ribose polymerase inhibitor (PARPi)-based regimen (either as a treatment or as maintenance).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
152 participants (estimated)

Study arms

  • Experimental
    Substudy 1 Part A(SS1A): escalating dose levels of palacaparib in combination with AZD2265(FPI-2265)

    Participants will receive escalating dose levels of palacaparib (AZD9574) once daily in combination with AZD2265 (FPI-2265) once every 6 weeks (Q6W).

    Drug: AZD2265 (FPI-2265) · Drug: Palacaparib (AZD9574) · Drug: AZD2287 (Imaging agent)

  • Experimental
    Sub study 1 Part B(SS1B): selected dose of palacaparib in combination with AZD2265(FPI-2265)

    Participants will receive palacaparib (AZD9574) chosen from the DE phase once daily in combination with AZD2265 (FPI-2265) Q6W.

    Drug: AZD2265 (FPI-2265) · Drug: Palacaparib (AZD9574) · Drug: AZD2287 (Imaging agent)

  • Experimental
    SS1B: AZD2265 (FPI-2265) monotherapy

    Participants will receive AZD2265 (FPI-2265) monotherapy Q6W.

    Drug: AZD2265 (FPI-2265) · Drug: AZD2287 (Imaging agent)

  • Active comparator
    SS1B: Docetaxel

    Participants will receive docetaxel as a standard of care (SoC) once every 3 weeks (Q3W).

    Drug: Docetaxel · Drug: AZD2287 (Imaging agent)

Interventions

  • AZD2265 (FPI-2265) will be administered as an intravenous (IV) injection.

    Also known as: FPI-2265, 225Ac-PSMA-I&T

  • Palacaparib (AZD9574) will be administered orally.

  • Docetaxel will be administered as an IV infusion.

  • DrugAZD2287 (Imaging agent)

    AZD2287 will be administered as an IV injection.

06

What researchers measure

Primary outcomes

  1. Part A: Number of participants with treatment-emergent adverse events (TEAEs)including serious adverse events (SAEs), treatment-related AEs (TRAEs) and adverse events of special interests (AESIs)

    To assess the safety and tolerability of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: Up to approximately 1 year after last dose

  2. Part A: Number of participants with dose limiting toxicities (DLTs)

    To assess the safety and tolerability, and characterise the DLTs of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: From date of first dose up to approximately 2 cycles (up to 3 months)

  3. Part B: Number of participants with TEAEs

    To further assess the safety and tolerability, and determine the recommended Phase 3 dose (RP3D) of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: Up to approximately 1 year after last dose

  4. Part B: Prostate Specific Antigen 50 (PSA50) response rate

    PSA50 response rate is defined as proportion of participants achieving a ≥ 50% decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later, and occurring prior to confirmed PSA progression. PSA50 will be assessed to check the anti-tumour activity of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: Up to 3 years 4 months

Secondary outcomes

  1. Part A and Part B: PSA50 response rate

    PSA50 response rate is defined as proportion of participants achieving a ≥ 50% decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later, and occurring prior to confirmed PSA progression. PSA50 will be assessed to check the anti-tumour activity of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265) (Part A) and to demonstrate effectiveness of AZD2265 (FPI-2265) + palacaparib (AZD9574) relative to AZD2265 (FPI-2265) alone and relative to docetaxel (Part B).

    Time frame: Up to 3 years 4 months

  2. Part A and Part B: Prostate Specific Antigen 90 (PSA90) response rate

    PSA90 response rate is defined as proportion of participants achieving a ≥ 90% decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later, and occurring prior to confirmed PSA progression. PSA90 will be assessed to check the anti-tumour activity of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265) (Part A and Part B) and to demonstrate effectiveness of AZD2265 (FPI-2265) + palacaparib (AZD9574) relative to AZD2265 (FPI-2265) alone and relative to docetaxel (Part B only).

    Time frame: Up to 3 years 4 months

  3. Part A and Part B: Time to PSA50 (TTPSA50) response

    TTPSA50 response is defined as the time from date of randomisation/first dose of study intervention until the date of first documented PSA50 response (≥ 50% decrease in PSA from baseline), confirmed by a second consecutive PSA assessment at least 3 weeks later. TTPSA50 response will be assessed to check the anti-tumour activity of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: Up to 3 years 4 months

  4. Part A and Part B: Time to PSA90 (TTPSA90) response

    TTPSA90 response is defined as the time from date of randomisation/first dose of study intervention until the date of first documented PSA90 response (≥ 90% decrease in PSA from baseline, respectively), confirmed by a second consecutive PSA assessment at least 3 weeks later. TTPSA90 response will be assessed to check the anti-tumour activity of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: Up to 3 years 4 months

  5. Part A and Part B: Duration of PSA50 (DoPSA50) response

    DoPSA50 response is defined as the time from the date of first documented PSA50 response, that is subsequently confirmed by a second consecutive PSA assessment at least 3 weeks later, until the date of documented PSA progression. DoPSA50 response will be assessed to check the anti-tumour activity of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: Up to 3 years 4 months

  6. Part A and Part B: Duration of PSA90 (DoPSA90) response

    DoPSA90 response is defined as the time from the date of first documented PSA90 response, that is subsequently confirmed by a second consecutive PSA assessment at least 3 weeks later, until the date of documented PSA progression. DoPSA90 response will be assessed to check the anti-tumour activity of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: Up to 3 years 4 months

  7. Part A and Part B: Time to PSA progression

    TTPSA progression is defined as time from the date of randomisation/first dose of study intervention until the date of documented PSA progression or the last PSA result in the absence of progression. PSA progression is defined as an increase in PSA of ≥ 25% from the nadir and an absolute increase of at least 2 ng/mL above nadir beyond 12 weeks. PSA progression must be confirmed by a second value taken at least 3 weeks later. TTPSA progression will be assessed to check the anti-tumour activity of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: Up to 3 years 4 months

  8. Part A and Part B: PSA over time

    PSA over time is defined as the longitudinal change in serum PSA from baseline across all on-study timepoints. PSA over time will be assessed to check the anti-tumour activity of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: Up to 3 years 4 months

  9. Part A and Part B: Radiographic Progression-free survival (rPFS)

    rPFS is defined as the time from date of randomisation/first dose of study intervention until the date of objective disease progression according to response evaluation criteria in solid tumors (RECIST) 1.1 (for soft tissue disease) and prostate cancer working group 3 (PCWG3) criteria (for bone disease) as assessed by the investigator at the local site, or death (by any cause in the absence of progression), regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy prior to progression. rPFS will be assessed to check the anti-tumour activity of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265) (Part A and Part B) and to demonstrate effectiveness of AZD2265 (FPI-2265) + palacaparib (AZD9574) relative to AZD2265 (FPI-2265) alone and relative to docetaxel (Part B only).

    Time frame: From Day 1 to 3 years 4 months

  10. Part A and Part B: Overall Response Rate (ORR)

    The ORR is defined as the percentage of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as the time from the date of first documented objective response (which is subsequently confirmed) until the date of radiographic disease progression or censored according to rules for rPFS. The ORR will be assessed to check the anti-tumour activity of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265) (Part A and Part B) and to demonstrate effectiveness of AZD2265 (FPI-2265) + palacaparib (AZD9574) relative to AZD2265 (FPI-2265) alone and relative to docetaxel (Part B only).

    Time frame: From Day 1 to 3 years 4 months

  11. Part A and Part B: Best Overall Response (BOR)

    The BOR is defined as the best overall visit response the participant achieves as determined by the investigator at the local site. The BOR will be assessed to check the anti-tumour activity of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265) (Part A and Part B) and to demonstrate effectiveness of AZD2265 (FPI-2265) + palacaparib (AZD9574) relative to AZD2265 (FPI-2265) alone and relative to docetaxel (Part B only).

    Time frame: From Day 1 to 3 years 4 months

  12. Part A and Part B: Duration of response (DoR)

    The DoR is defined based on RECIST 1.1 (for soft tissue disease) and PCWG3 criteria (for bone disease) as the time from the date of first documented objective response (which is subsequently confirmed) until date of radiographic disease progression or censored according to rules for rPFS. The DoR will be assessed to check the anti-tumour activity of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265) (Part A and Part B) and to demonstrate effectiveness of AZD2265 (FPI-2265) + palacaparib (AZD9574) relative to AZD2265 (FPI-2265) alone and relative to docetaxel (Part B only).

    Time frame: From Day 1 to 3 years 4 months

  13. Part A and Part B: Time to Response (TTR)

    The TTR is defined as the time from the date of randomisation/first dose of study intervention until the date of first documented objective response, which is subsequently confirmed. The TTR will be assessed to check the anti-tumour activity of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265) (Part A and Part B) and to demonstrate effectiveness of AZD2265 (FPI-2265) + palacaparib (AZD9574) relative to AZD2265 (FPI-2265) alone and relative to docetaxel (Part B only).

    Time frame: From Day 1 to 3 years 4 months

  14. Part A: Disease control rate (DCR)

    To assess the anti-tumour activity of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265)

    Time frame: From Day 1 to 3 years 4 months

  15. Part A and Part B: Percentage change in tumour size

    To assess the anti-tumour activity of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: From Day 1 to 3 years 4 months

  16. Part A and Part B: Plasma concentration of palacaparib (AZD9574)

    To determine the PK of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 15 (each cycle will be 42 days)

  17. Part A and Part B: Plasma concentration of AZD2265 (FPI-2265)

    To determine the PK of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle will be 42 days)

  18. Part A and Part B: Area under the concentration time curve (AUC)

    To determine the PK (AUC) of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 15 (each cycle will be 42 days)

  19. Part A and Part B: Maximum observed drug concentration (Cmax)

    To determine the PK (Cmax) of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 15 (each cycle will be 42 days)

  20. Part A and Part B: Time to reach Cmax (tmax)

    To determine the PK (tmax) of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 15 (each cycle will be 42 days)

  21. Part A and Part B: Terminal elimination half-life (t½λz)

    To determine the PK (t½λz) of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 15 (each cycle will be 42 days)

  22. Part A and Part B: Change from baseline in study-specific biomarker ABC in response to treatment

    To investigate pharmacodynamics of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265) (for Part A and Part B) and of AZD2265 (FPI-2265) monotherapy (for Part B only).

    Time frame: Up to 3 years 4 months

  23. Part A and Part B: Change from baseline in study-specific biomarker XYZ in response to treatment

    To investigate study-specific XYZ expression and relationship to response to the treatment.

    Time frame: Up to 3 years 4 months

07

Study locations

3 of 38 sites recruiting
  • Research Site
    Duarte, California 91010, United States
    Not yet recruiting
  • Research Site
    Encino, California 91436, United States
    Not yet recruiting
  • Research Site
    South Pasadena, California 91030, United States
    Recruiting
  • Research Site
    Miami, Florida 33165, United States
    Recruiting
  • Research Site
    Orlando, Florida 32806, United States
    Not yet recruiting
  • Research Site
    Tampa, Florida 33612, United States
    Not yet recruiting
  • Research Site
    Metairie, Louisiana 70006, United States
    Not yet recruiting
  • Research Site
    Minneapolis, Minnesota 55455, United States
    Not yet recruiting
  • Research Site
    Omaha, Nebraska 68130, United States
    Recruiting
  • Research Site
    New York, New York 10065, United States
    Not yet recruiting
  • Research Site
    Portland, Oregon 97239, United States
    Not yet recruiting
  • Research Site
    Houston, Texas 77030, United States
    Not yet recruiting
  • Research Site
    North Adelaide, 5000, Australia
    Not yet recruiting
  • Research Site
    Essen, 45147, Germany
    Not yet recruiting
  • Research Site
    Jena, 07747, Germany
    Not yet recruiting
  • Research Site
    Rostock, 18057, Germany
    Not yet recruiting
  • Research Site
    Tübingen, 72076, Germany
    Not yet recruiting
  • Research Site
    Bergamo, 24127, Italy
    Not yet recruiting
  • Research Site
    Meldola, 47014, Italy
    Not yet recruiting
  • Research Site
    Milan, 20133, Italy
    Not yet recruiting
  • Research Site
    Milan, 20141, Italy
    Not yet recruiting
  • Research Site
    Roma, 00168, Italy
    Not yet recruiting
  • Research Site
    Seoul, 03080, South Korea
    Not yet recruiting
  • Research Site
    Seoul, 03722, South Korea
    Not yet recruiting
  • Research Site
    Seoul, 06351, South Korea
    Not yet recruiting
  • Research Site
    Seoul, 06591, South Korea
    Not yet recruiting
  • Research Site
    Seoul, 5505, South Korea
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Barcelona, 08028, Spain
    Not yet recruiting
  • Research Site
    L'Hospitalet de Llobregat, 08908, Spain
    Not yet recruiting
  • Research Site
    Madrid, 28031, Spain
    Not yet recruiting
  • Research Site
    Madrid, 28041, Spain
    Not yet recruiting
  • Research Site
    Pamplona, 31008, Spain
    Not yet recruiting
  • Research Site
    Belfast, BT9 7AB, United Kingdom
    Not yet recruiting
  • Research Site
    Fulham, SW3 6JJ, United Kingdom
    Not yet recruiting
  • Research Site
    Guildford, CU2 7XX, United Kingdom
    Not yet recruiting
  • Research Site
    London, WC1E 6DB, United Kingdom
    Not yet recruiting
  • Research Site
    Newcastle upon Tyne, NE7 7DN, United Kingdom
    Not yet recruiting
  • Research Site
    Oxford, OX3 7LE, United Kingdom
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Sep 2029, 39 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 39 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 15, 2026
StartActual
Jun 3, 2026
Primary completionEst.
Sep 25, 2029
CompletionEst.
Sep 25, 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. Research Site is now Recruiting
Show site
  • Research Site · Orlando, United States
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    1 site added. Research Site is now Recruiting
    Show site
    • Research Site · Orlando, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07590934
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 15, 2026
Start date
Jun 3, 2026
Primary completion
Sep 25, 2029 (estimated)
Completion
Sep 25, 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Actinium zadavotide guraxetan AC-225 · Palacaparib

Start the discussion